A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.